Aiolos regulates eosinophil migration into tissues.

Area of Science:

• Immunology
• Molecular Biology
• Transcription Factor Research

Background:

• The transcription factor IKZF3, also known as Aiolos, is upregulated during eosinophil development.
• Its precise role in mature human and murine eosinophils remains largely uncharacterized.

Purpose of the Study:

• To investigate the expression and functional significance of Aiolos in mature eosinophils.
• To determine the impact of Aiolos deficiency on eosinophil function and inflammatory responses.
• To explore Aiolos as a potential therapeutic target in eosinophilic diseases.

Main Methods:

• Analysis of Aiolos expression in human and murine eosinophils.
• Gene expression profiling and ATAC-seq in Aiolos-deficient murine eosinophils.
• Chimeric mouse models to assess intrinsic Aiolos function.
• Flow cytometry for CCR3 surface expression and intracellular signaling.
• Functional assays for chemotaxis and actin polymerization.
• ChIP-seq analysis in human eosinophils and lenalidomide treatment of EOL-1 cells.

Main Results:

• Aiolos deficiency alters gene expression in pathways critical for granulocyte immunity, chemotaxis, and degranulation.
• Aiolos-deficient eosinophils exhibit reduced CCR3 expression, impaired ERK1/2 signaling, and diminished CCL11-induced actin polymerization.
• Global and intrinsic Aiolos deficiency reduces eosinophil frequency and tissue accumulation in homeostatic and inflammatory models.
• Human eosinophil chromatin is marked by regulatory elements bound by Aiolos, PU.1, and GATA-1.
• Lenalidomide treatment decreases Aiolos expression in a human eosinophilic cell line.

Conclusions:

• Eosinophil homing during homeostasis and allergic inflammation is dependent on Aiolos.
• Aiolos plays a critical role in regulating eosinophil function, including chemotaxis and degranulation.
• Aiolos represents a promising therapeutic target for managing eosinophilic diseases.